Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4028 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Chemokine re-acquires compound from PPD

Under the agreement, Chemokine will pay Pharmaceutical Product Development (PPD) $100,000 cash on closing, and up to $2.5 million in milestone payments upon achievement of developmental, regulatory and

YM BioSciences to acquire Eximias

The acquisition is designed to amplify YM’s critical mass, specifically in its management team and cash resources. It will allow YM to expand capabilities for the development and

Sanofi antibiotic may alleviate asthma

Results from a multinational study published in the New England Journal of Medicine show that Sanofi’s telithromycin antibiotic, sold under the brand name Ketek, could help patients recover

UK takes action on medical research fraud

Recent years have seen much debate focused around how best to monitor and regulate research integrity to help prevent misconduct. Unlike certain other countries, including the US and

Teva gets approval for Serono generic

Teva said it will begin shipping the product immediately. Named Mitoxantrone Hydrochloride Injection USP, the treatment will be indicated for use in combination with corticosteroids as initial therapy

Stem Cell Innovations targets Europe

The company operates to give pharmaceutical & biotech companies a toxicity testing platform to assist them in streamlining their development pipeline by selecting the right molecules early in